ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,930.85
      1.09%
      US Tech 100
      20,836.00
      1.31%
      Dow Jones
      42,840.26
      1.18%
      Brent Oil
      72.72
      0.00%
      Bitcoin
      97,494.44
      -0.28%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Akebia Therapeutics Inc (AKBA) Quote

      Akebia Therapeutics Inc

      Akebia Therapeutics Inc (AKBA)

      NASDAQ
      1.83
      0.04
      (2.23%)
      Closed December 21 4:00PM
      Delayed by 15 minutes
      1.8798
      0.0498
      (2.72%)
      After Hours: 7:44PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      1.8798
      Bid
      1.79
      Ask
      2.10
      Volume
      5,912,325
      1.75 Day's Range 1.87
      0.80 52 Week Range 2.48
      Market Cap
      410.137M
      Previous Close
      1.79
      Open
      1.77
      Last Trade
      43
      @
      1.87
      Last Trade Time
      Financial Volume
      $ 10,706,079
      VWAP
      1.8108
      Average Volume (3m)
      1,960,253
      Shares Outstanding
      218,181,202
      Dividend Yield
      -
      PE Ratio
      -7.69
      Earnings Per Share (EPS)
      -0.24
      Revenue
      194.62M
      Net Profit
      -51.93M

      About Akebia Therapeutics Inc

      Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment... Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.akebia.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Akebia Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AKBA. The last closing price for Akebia Therapeutics was $1.79. Over the last year, Akebia Therapeutics shares have traded in a share price range of $ 0.80 to $ 2.48.

      Akebia Therapeutics currently has 218,181,202 shares outstanding. The market capitalization of Akebia Therapeutics is $390.54 million. Akebia Therapeutics has a price to earnings ratio (PE ratio) of -7.69.

      Ask ADVFN Intelligence (AI)

      AKBA Latest News

      More News

      Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass., Dec. 18, 2024 CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Akebia...

      December 18 2024
      PR Newswire (US)

      Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Dec. 3, 2024 CAMBRIDGE, Mass., Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®...

      December 03 2024
      PR Newswire (US)

      U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

      U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis PR Newswire CAMBRIDGE, Mass., Dec. 3, 2024 Outcomes study...

      December 03 2024
      PR Newswire (US)

      Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

      Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference PR Newswire CAMBRIDGE, Mass., Nov. 25, 2024 CAMBRIDGE, Mass., Nov. 25, 2024 /PRNewswire/ -- Akebia...

      November 25 2024
      PR Newswire (US)

      Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

      Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease PR Newswire CAMBRIDGE, Mass., Nov. 14, 2024 Akebia continues to publish important results of FO2CUS...

      November 14 2024
      PR Newswire (US)

      Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

      Akebia Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire CAMBRIDGE, Mass., Nov. 12, 2024 CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Akebia Therapeutics®...

      November 12 2024
      PR Newswire (US)

      Form SC 13G - Statement of Beneficial Ownership by Certain Investors

      November 08 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 07 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 07 2024
      Edgar (US Regulatory)

      Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR Newswire CAMBRIDGE, Mass., Nov. 7, 2024 Vafseo® (vadadustat) on track for U.S. market...

      November 07 2024
      PR Newswire (US)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.07984.433333333331.81.91.7418378981.81532935CS
      40.04982.721311475411.832.171.7421087571.95656081CS
      120.539840.28358208961.342.171.2419602531.77524122CS
      260.869886.11881188121.012.170.823090721.43054277CS
      520.679856.651.22.480.829345221.50948157CS
      156-0.5102-21.34728033472.392.930.24136253111.01337625CS
      260-4.3502-69.82664526486.2313.780.24136619992.2463783CS

      AKBA - Frequently Asked Questions (FAQ)

      What is the current Akebia Therapeutics share price?
      The current share price of Akebia Therapeutics is $ 1.8798
      How many Akebia Therapeutics shares are in issue?
      Akebia Therapeutics has 218,181,202 shares in issue
      What is the market cap of Akebia Therapeutics?
      The market capitalisation of Akebia Therapeutics is USD 390.54M
      What is the 1 year trading range for Akebia Therapeutics share price?
      Akebia Therapeutics has traded in the range of $ 0.80 to $ 2.48 during the past year
      What is the PE ratio of Akebia Therapeutics?
      The price to earnings ratio of Akebia Therapeutics is -7.69
      What is the cash to sales ratio of Akebia Therapeutics?
      The cash to sales ratio of Akebia Therapeutics is 2.05
      What is the reporting currency for Akebia Therapeutics?
      Akebia Therapeutics reports financial results in USD
      What is the latest annual turnover for Akebia Therapeutics?
      The latest annual turnover of Akebia Therapeutics is USD 194.62M
      What is the latest annual profit for Akebia Therapeutics?
      The latest annual profit of Akebia Therapeutics is USD -51.93M
      What is the registered address of Akebia Therapeutics?
      The registered address for Akebia Therapeutics is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
      What is the Akebia Therapeutics website address?
      The website address for Akebia Therapeutics is www.akebia.com
      Which industry sector does Akebia Therapeutics operate in?
      Akebia Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MYSZMy Size Inc
      $ 4.2001
      (211.12%)
      		121.03M
      NVNINVNI Group Ltd
      $ 8.26
      (209.36%)
      		78.06M
      TPICTPI Composites Inc
      $ 2.45
      (100.82%)
      		34M
      ICGIntchains Group Ltd
      $ 8.77
      (88.60%)
      		527.94k
      HSDTHelius Medical Technologies Inc
      $ 0.884851
      (84.34%)
      		121.95M
      CYNCYNGN Inc
      $ 0.4603
      (-71.41%)
      		27.91M
      MTEMMolecular Templates Inc
      $ 0.1502
      (-57.09%)
      		8.75M
      PRFXPainReform Ltd
      $ 5.15
      (-53.85%)
      		2.94M
      GALTGalectin Therapeutics Inc
      $ 1.03
      (-48.50%)
      		9.27M
      BCABBioAtla Inc
      $ 0.6923
      (-41.82%)
      		6.25M
      EDBLEdible Garden AG Inc
      $ 0.24
      (65.06%)
      		354.32M
      APTOAptose Biosciences Inc
      $ 0.28
      (64.51%)
      		305.1M
      TNXPTonix Pharmaceuticals Holding Corporation
      $ 0.606999
      (6.49%)
      		292.16M
      NVDANVIDIA Corporation
      $ 134.70
      (3.08%)
      		287.21M
      PLTRPalantir Technologies Inc
      $ 80.55
      (8.54%)
      		277.63M

      AKBA Discussion

      View Posts
      glenn1919 glenn1919 3 weeks ago
      AKBA.....................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      TrendTrade2016 TrendTrade2016 1 month ago
      AKBA BIO BEAST INTO FDA
      👍️0
      TrendTrade2016 TrendTrade2016 2 months ago
      AKBA BEASTING LONG...FDA APPROVED DRUG COMES TO MARKET IN JAN
      👍️0
      TrendTrade2016 TrendTrade2016 2 months ago
      AKBA BUILDING 1.79 BREAK IS COMING
      👍️0
      TrendTrade2016 TrendTrade2016 2 months ago
      AKBA GAPPING AND READY FOR 1.79
      👍️0
      TrendTrade2016 TrendTrade2016 2 months ago
      AKBA BACK IN PLAY UNTIL JAN 2025...FDA COMING
      👍️0
      glenn1919 glenn1919 4 months ago
      AKBA.....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 4 months ago
      AKBA................................https://stockcharts.com/h-sc/ui?s=ARKB&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 4 months ago
      AKBA......................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 5 months ago
      AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      Krspecialized Krspecialized 5 months ago
      I believe the current news releases may have answered your question. GLTA
      👍️0
      Toofuzzy Toofuzzy 7 months ago
      Why do you say we have a gold mine here ?

      Toofuzzy
      👍️0
      Krspecialized Krspecialized 7 months ago
      There's no doubt we have a gold mine here, and at some point it will be load up time. Figuring out when is the big question!
      👍️0
      eyeownu eyeownu 7 months ago
      SCARY MOVIE
      👍️0
      eyeownu eyeownu 7 months ago
      https://journey.ct.events/view/a825b116-e5ee-4e76-ad8d-2e9e9116aa21 tomorrows web cast
      👍️0
      eyeownu eyeownu 7 months ago
      added 2k@ 1.11
      👍️ 1
      glenn1919 glenn1919 8 months ago
      AKBA................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 8 months ago
      AKBA under $2

      👍️0
      eyeownu eyeownu 8 months ago
      ask is stacked! someone needs to slap it.
      👍️0
      eyeownu eyeownu 8 months ago
      $AKBA RELOAD
      👍️0
      Firestorm22 Firestorm22 8 months ago
      Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
      👍️0
      Firestorm22 Firestorm22 8 months ago
      Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
      👍️0
      ErnieBilco ErnieBilco 9 months ago
      I'm in at 33 cents so I'm not going anywhere, just gonna let it ride wherever it goes
      👍️ 1
      Firestorm22 Firestorm22 9 months ago
      Thanks, I’m hanging onto it . With actual revenues of 40-60 mill the last 5 quarters, one would think this stock price should rise. I wouldn’t mind seeing them bought out.
      👍️ 1
      ErnieBilco ErnieBilco 9 months ago
      Classic sell the news. Probable offering coming next week to dilute on the good news.
      👍️0
      Firestorm22 Firestorm22 9 months ago
      Something just isnt right here. How do you get FDA approval for a drug and your stock price tank? Is there some bads news getting ready to come out on this company??
      👍️0
      Krspecialized Krspecialized 9 months ago
      Long solid position here!
      👍️0
      Limey42 Limey42 9 months ago
      Long term play. Congrats all!
      👍️ 1
      dugie100 dugie100 9 months ago
      Something didn’t look good , I guess!
      👍️0
      TrendTrade2016 TrendTrade2016 9 months ago
      AKBA should see 3 bucks
      👍️0
      TrendTrade2016 TrendTrade2016 9 months ago
      AKBA...FDA EXPLOSION ...WE LOADED THIS BEAUTY....KOCKED AND LOADED!!!!
      👍️0
      glenn1919 glenn1919 9 months ago
      AKBA...................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 9 months ago
      AKBA new 52 hi
      👍️0
      eyeownu eyeownu 9 months ago
      $AKBA looking good damn! she fine.
      👍️ 1
      glenn1919 glenn1919 9 months ago
      AKBA.................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      eyeownu eyeownu 9 months ago
      $AKBA from stocktwits FDA’S THREE ALARM FIRE- (a)FDA issued CRL to FibroGen & Roxadustat (Aug. 2021); (b)FDA issued CRL to Akebia & Vadadustat (March 2022); (c)FDA’s Cardiovascular & Renal Drugs Advisory Committee supported GSK’s Daprodustat for dialysis dependent patients w/ anaemia of CKD w/ 13-3 vote (Oct. 2022); (d)Akebia submitted FDRR w/ FDA’s Senior Advisor in agency’s Office of New Drugs (OND) (Nov. 2022); (e)CKD community & key opinion leaders such as Dr. Jay Wish criticize FDA decision making concerning HIF-PHI drugs (March 2022 - present). (FDA knows from data that Daprodustat is inferior to Vadadustat.) FDA’S RESPONSE TO FIRE - (a)FDA met w/ Akebia to discuss appeal & subsequently requested “additional clarifying information” (not ADCOM, not clinical trial, not denial) (Nov. 2022); (b)FDA assigned Dr. Peter Stein, M.D., Director of OND as deciding authority for appeal (Feb. 2023); (c)Dr. Stein provided Akebia/Vadadustat w/ clear path forward to approval (May 2023). GLTA
      👍️ 1
      Monksdream Monksdream 10 months ago
      AKBA 10Q March 4
      👍️0
      Tyrus603 Tyrus603 10 months ago
      Excellent chart. Thank you for posting.

      Found myself studying it for quite a bit.

      As it really is a dream chart for both swing traders AND long term buy & hold investors alike.
      👍️0
      glenn1919 glenn1919 10 months ago
      AKBA..............................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      eyeownu eyeownu 10 months ago
      $AKBA
      👍️0
      eyeownu eyeownu 10 months ago
      $AKBA reversal incoming?
      👍️0
      eyeownu eyeownu 11 months ago
      CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to $55.0 million of borrowing capacity available in three tranches.

      At the closing, Akebia drew the first tranche of $37.0 million and used the proceeds to pay down $35.0 million of principal outstanding from a loan agreement with Pharmakon Advisors, LP (Pharmakon), the investment manager of the BioPharma Credit funds, plus interest and fees. The new agreement substantially extends the interest-only period in the event of vadadustat approval by the U.S. Food and Drug Administration (FDA) without requiring any principal repayment until December 31, 2025, with an option for Akebia to extend until December 31, 2026.
      👍️0
      eyeownu eyeownu 11 months ago
      $AKBA profit taking! hope you took some off the table!
      👍️0
      eyeownu eyeownu 11 months ago
      PDUFA explanation https://www.fool.com/terms/p/pdufa-date/

      What percentage of PDUFA are approved?
      Characteristic Percentage of drugs approved in 2023
      Met PDUFA goal date* 89%
      First cycle of review 84%
      Approved in the United States before receiving approval in any other country 64%
      Priority review 56%

      From
      👍️0
      eyeownu eyeownu 11 months ago
      $AKBA via stocktwit @Bidzill @fresh10 fresh - We have PDUFA date scheduled for March 27, 2024 concerning Vadadustat DD USA. Approval is de-risked and highly likely, IMO. We have product launch date first half of year for Vadadustat DD EU/Australia. We have phase 2 trial for AKB 9090 for second half of 2024. We have Auryxia all time/near all time high sales 2024. Good luck 🍀 to you and us.
      👍️0
      eyeownu eyeownu 11 months ago
      https://www.tradingview.com/x/6Ykwijbc/
      👍️0
      eyeownu eyeownu 11 months ago
      $AKBA from stocktwits

      MORE GOOD NEWS - FDA Fast Track Designation is process designed to facilitate development & expedite drug review to treat serious conditions & fill UNMET MEDICAL NEED. Determining whether condition is serious enough for designation is matter of judgment … ARDS is life threatening & acute, diffuse, inflammatory form of lung injury in seriously ill patients characterized by poor oxygenation, pulmonary infiltrates, acute onset. Unadjusted hospitalization mortality was reported to be 35% among those w/ mild ARDS, 40% w/ moderate disease, 46% for patients w/ severe ARDS. AKB 9090 is Akebia’s ARDS drug. Filling an unmet need is defined as providing therapy where none exists or which may be potentially better than available therapy. Drug that receives Fast Track is eligible for accelerated approval/priority review. August of 2022, CEO Butler said Vadadustat was in trials for Covid-19/ARDS which was an “unmet medical need.” Butler was signaling intention to go after Fast Track status.
      https://stocktwits.com/buythehornz127/message/559186953
      👍️0
      eyeownu eyeownu 11 months ago
      John P. Butler, President and Chief Executive Officer of Akebia Therapeutics, Inc. (the “Company”), plans to present the information in the presentation attached hereto as Exhibit 99.1 (the “Presentation”) at the 42 Annual J.P. Morgan
      Healthcare Conference on January 11, 2024 at 11:15 a.m. PST, which includes preliminary unaudited net product revenue for Auryxia® cumulative and for the fiscal year ended December 31, 2023. Spokespersons of the Company also plan
      to present the information in the Presentation at various meetings beginning on January 8, 2024, including investor and analyst meetings that coincide with the J.P. Morgan Healthcare Conference

      https://ir.akebia.com/static-files/0be66d7f-9988-43fa-bcab-e587260e1dc0
      👍️0
      eyeownu eyeownu 11 months ago
      easy money https://schrts.co/JdqbEsCN wait till the real news drops!
      👍️0
      eyeownu eyeownu 11 months ago
      $AKBA shabba https://schrts.co/bYSHjBzF
      👍️0

      Your Recent History

      NASDAQ
      AKBA
      Akebia Therapeutics
      BIT
      NSCITOTENOE2
      Portugal Republik
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads